News & Updates


Dr. Martin Taylor Chairs Conference focusing on Craniofascial Pain & Dystonia

Update-on-Craniofacial-Pain-and-Dystonia-logo-2016-600x346 NANA 2016

Dr. Martin Taylor  (Course Chairman), OrthoNeuro Neurologist will be presenting at the upcoming NANA continuing medical education conference.

September 23-24, 2016
Mt. Carmel Education Center
7333 Smith’s Mill Road
New Albany, OH 43054

Conference Overview:

Joint providers, University of Cincinnati and MedEd Consulting, Inc., in collaboration with the North American Neurotoxin Association (NANA) and the North Central Headache Society (NCHS) are organizing a 1.5-Day Conference.

The goal of the conference, Update on Craniofacial Pain and Dystonia, is to educate practitioners in the mechanism of action, therapeutic rationale, and clinical application of botulinum neurotoxin in the management of patients with head and neck dysfunction. The NANA/NCHS Tandem Conference is offering up to 9.5 AMA PRA Category 1 Credits ™.

The North American Neurotoxin Association (NANA) is a multidisciplinary organization created to educate physicians and other healthcare professionals concerned with the fundamental principles surrounding and appropriate usage of botulinum toxin injections. NANA provides several ACCME accredited educational events annually. The programs are fully interactive with case-based presentations and workshops that review the mechanism of action, therapeutic rationale, and clinical application of botulinum neurotoxin.

The North Central Headache Society (NCHS), previously known as the Ohio Headache Association, has conducted educational activities since its inception in the late 1990s. Founded by Drs. Robert Kunkel and Robert Smith, the society’s membership includes headache physicians from Ohio, Pennsylvania, Indiana, Kentucky and West Virginia. The society has also sponsored research projects that have investigated the relationship between migraines and comorbid medical conditions.

Target Audience:

This course is designed for physicians, including neurologists, pediatricians, internists, family medicine physicians, physiatrists, and pain specialists as well as nurse practitioners, physician assistants, registered nurses, physical therapists, residents, students, practitioners treating head, neck, and facial pain, and all other healthcare professionals with an interest in the clinical application of botulinum neurotoxin in the management of patients with head and neck dysfunction.

Learning Objectives:

At the conclusion of this activity, learners will be able to:

Discuss the mechanism of action and the conceptual basis for the use of therapeutic botulinum neurotoxin therapy in patients with oromandibular dystonia and bruxism / temporomandibular dysfunction, blepharospasm, cervical dystonia, migraine headache, cervicogenic headache, and neck pain

Summarize the scientific data on the analgesic properties of BoNT in treating patients with head and neck dysfunction

Explain the safety and efficacy of botulinum serotypes approved by the FDA for clinical use

Describe the diagnosis and treatments for facial pain and headache in pediatrics

Review the clinical criteria for the classification of migraine and inpatient refractory headaches

Discuss the association between headaches and sleep apnea, bruxism/temporomandibular dysfunction, allergies and sinus disorders

Identify techniques for the safe and effective injection of botulinum toxin/nerve blocks/sphenocath for headaches